{"success":true,"data":{"pressRelease":{"id":"130642","rtpr_id":"nGNX91PQ3L","ticker":"TRIB","exchange":"NASDAQ","all_tickers":["TRIB"],"title":"Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update","author":"Globe Newswire","published_at":"2026-08-28T21:15:00.108Z","article_body":"- Continued execution of transformation strategy drives commercial,\nmanufacturing and pipeline progress\n\n- PrePsia™ patent portfolio expands to nine granted U.S. and European\npatents\n\n- Company issues update on Nasdaq listing\n\nDUBLIN, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB),\na commercial-stage biotechnology company focused on human diagnostics and\ndiabetes management solutions, today provided an update on key developments\nacross its diagnostics business, highlighting continued commercial progress,\noperational transformation and diagnostic pipeline advancement.\n\nStrengthening Commercial Leadership in Europe\n\nTrinity Biotech is pleased to announce that Jordi Romero has joined the\nCompany as Head of Commercial Operations – Europe. Mr. Romero brings\nextensive experience in diagnostic sales, marketing and commercial leadership,\nincluding significant expertise within the haemoglobin diagnostics market. He\njoins Trinity at an important stage in the Company's transformation as it\nseeks to accelerate profitable growth across its diagnostics franchise in\nEurope and other international markets. \n\nMr. Romero's appointment forms part of Trinity's broader strategy to\nstrengthen its commercial organisation, deepen customer engagement and enhance\nexecution across key international markets.\n\nContinued Rollout of Upgraded HbA1c Column Technology\n\nThe Company also announced continued progress in the commercial rollout of its\nnext-generation high-capacity HbA1c column system for the FDA-cleared Premier\nHb9210™ analyser. Trinity has now successfully completed rollout of the\nupgraded column system in three of its largest international markets and is\nreceiving positive customer feedback regarding performance and overall user\nexperience.\n\nDesigned for Trinity Biotech’s Premier Hb9210™ analyser, the Company’s\ndedicated laboratory HbA1c solution, the upgraded column system delivers up to\nfour times the testing capacity compared to the existing column system and\nminimizes instrument downtime through improved stability and reduced\ncalibration requirements. These operational gains create a more efficient\nworkflow for clinical laboratories and support broader adoption of the\nplatform.\n\nThe Company expects continued deployment across additional markets over the\ncoming quarters.\n\nOperational Transformation Driving Margin and Working Capital Benefits\n\nTrinity continues to execute its comprehensive operational transformation\nprogramme, including the transition of significant portions of the\nmanufacturing process for its World Health Organization-approved rapid HIV\ntest portfolio to an outsourced manufacturing structure.\n\nThe Company has successfully completed manufacture of the previously announced\napproximately 9 million TrinScreen HIV tests under this new operating model\nand has now also commenced manufacture of Uni-Gold™ HIV utilising its\noutsourced manufacturing structure.\n\nThe Company remains focused on scaling Uni-Gold™ HIV production and has\ncurrently a strong order book for the product.\n\nOnce fully scaled, the Company expects the outsourced manufacturing model to\ndeliver meaningful improvements in gross margin performance, manufacturing\nefficiency and working capital utilisation.\n\nAs previously indicated, the transition and scale-up process may result in\nquarter-to-quarter variability in Uni-Gold™ HIV revenues during the ramp-up\nperiod as manufacturing output continues to increase and supply chain\ninventories are optimised.\n\nContinued Advancement of the Diagnostics Pipeline\n\nTrinity also continues to advance its pipeline of innovative diagnostic\nproducts.\n\nMost recently, the Company received a European patent covering the use of\nblood pressure-related metrics in its PrePsia™ early preeclampsia prediction\nplatform. This brings the total number of PrePsia™ related granted patents\nacross Europe and the United States to nine and further strengthens the\nintellectual property protection around the Company’s maternal health\nprogramme.\n\nPrePsia™ is being developed as an early screening test designed to identify\npregnancies at increased risk of preterm preeclampsia, one of the leading\ncauses of maternal and foetal morbidity worldwide. The Company believes the\ncontinued expansion of the intellectual property portfolio supporting\nPrePsia™, and its underpinning technologies, strengthens the foundation for\nfuture commercialisation opportunities in women's health diagnostics. \n\nThe Company intends to launch the PrePsia™ test through its existing New\nYork State Department of Health approved reference laboratory.\n\nTransformation Continues to Gain Momentum\n\nThe Company believes these achievements demonstrate continued execution\nagainst its strategy to transform Trinity Biotech into a more efficient,\ncommercially focused and innovation-driven diagnostics business.\n\nKey areas of progress include:\n* Strengthening commercial leadership and market execution.\n* Enhancing the competitiveness of the Premier Hb9210 platform.\n* Improving manufacturing efficiency through strategic outsourcing\ninitiatives.\n* Expanding intellectual property protection around high-value diagnostic\npipeline assets.\n* Positioning the business for sustainable margin expansion and profitable\ngrowth.\nNasdaq Notice \n\nAs previously reported in a Current Report on Form 6-K filed February  20,\n2026, on February  19, 2026, the Company received a deficiency letter from\nthe Listing Qualifications Department of The Nasdaq Stock Market LLC\n(“Nasdaq”) notifying the Company that, for the preceding 30 consecutive\nbusiness days, the market value of publicly held shares (\"MVPHS\") remained\nbelow the minimum $15 million for continued inclusion on The Nasdaq Global\nSelect Market pursuant to Nasdaq Listing Rule 5450(b)(3)(c) (the “MVPHS\nRequirement”). The Company was provided an extension of 180 calendar days,\nor until August 18, 2026, (the “Compliance Period”) to regain compliance\nwith the MVPHS Requirement. \n\nOn August 28, 2026, the Company received a staff determination letter (the\n“Determination Letter”) from the Staff notifying the Company that it had\nnot regained compliance with the MVPHS Requirement by August 18, 2026.\nAccordingly, and as described in the Determination Letter, unless the Company\ntimely requests a hearing before a Hearings Panel (the “Panel”), the\nCompany’s securities would be subject to suspension/delisting. Accordingly,\nthe Company intends to timely request a hearing before the Panel.\n\nThe Company has a number of initiatives and strategic transactions at advanced\nstages, which, if completed, would be expected to increase the Company’s\nMVPHS above the $15 million minimum. The Company intends to continue to\nprogress these transactions and as such management remains confident that the\nactions currently underway will enable the Company to reach a MVPHS of over\n$15 million.\n\nThe hearing request will automatically stay any suspension or delisting action\npending the hearing and the expiration of any additional extension period\ngranted by the Panel following the hearing. In that regard, pursuant to the\nNasdaq Listing Rules, the Panel has the authority to grant an extension not to\nexceed February 24, 2027.\n\nNotwithstanding the foregoing, there can be no assurance that the Panel will\ngrant the Company an additional extension period or that the Company will\nultimately regain compliance with all applicable requirements for continued\nlisting on The Nasdaq Global Select Market.  \n\nForward-Looking Statements\nThis release includes statements that constitute “forward-looking\nstatements” within the meaning of the Private Securities Litigation Reform\nAct of 1995 (the “Reform Act”), including but not limited to statements\nrelated to Trinity Biotech’s cash position, financial resources and\npotential for future growth, market acceptance and penetration of new or\nplanned product offerings, and future recurring revenues and results of\noperations. Trinity Biotech claims the protection of the safe harbor for\nforward-looking statements contained in the Reform Act. These forward-looking\nstatements are often characterized by the terms “may,” “believes,”\n“projects,” “expects,” “anticipates,” or words of similar import,\nand do not reflect historical facts. Specific forward-looking statements\ncontained in this release may be affected by risks and uncertainties,\nincluding, but not limited to, our ability to capitalize on the Waveform\ntransaction and our recent acquisitions, our continued listing on the Nasdaq\nStock Market, our ability to achieve profitable operations in the future, our\nability to successfully develop and commercialize data center cooling &\nthermal management solutions for AI and high-performance computing, the impact\nof the spread of COVID-19 and its variants, the possible pause and/or\ndisruption in U.S. Government funding for HIV tests produced by Trinity\nBiotech, potential excess inventory levels and inventory imbalances at the\nCompany’s distributors, losses or system failures with respect to Trinity\nBiotech’s facilities or manufacturing operations, the effect of exchange\nrate fluctuations on international operations, fluctuations in quarterly\noperating results, dependence on suppliers, the market acceptance of Trinity\nBiotech’s products and services, the continuing development of its products,\nrequired government approvals, risks associated with manufacturing and\ndistributing its products on a commercial scale free of defects, risks related\nto the introduction of new instruments manufactured by third parties, risks\nassociated with competing in the human diagnostic market, risks related to the\nprotection of Trinity Biotech’s intellectual property or claims of\ninfringement of intellectual property asserted by third parties, and risks\nrelated to the condition of the United States economy and other risks detailed\nunder “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for\nthe fiscal year ended December 31, 2025 and Trinity Biotech’s other periodic\nreports filed from time to time with the United States Securities and Exchange\nCommission. Forward-looking statements speak only as of the date the\nstatements were made. Trinity Biotech does not undertake and specifically\ndisclaims any obligation to update any forward-looking statements.\n\nAbout Trinity Biotech\nTrinity Biotech plc (NASDAQ: TRIB) is a commercial-stage biotechnology company\nfocused on human diagnostics and diabetes management solutions, including\nwearable biosensors. The Company develops, acquires, manufactures, and markets\ndiagnostic systems for the point-of-care and clinical laboratory segments of\nthe diagnostic market and has recently entered the wearable biosensor industry\nthrough the acquisition of biosensor assets from Waveform Technologies Inc.\nThrough its Trinovium subsidiary, Trinity Biotech is extending its fluid\nmanufacturing and analytical capabilities into advanced liquid cooling\nsolutions for AI data center infrastructure. Trinity Biotech sells directly in\nthe United States and through a network of international distributors and\nstrategic partners in over 75 countries worldwide. For further information,\nplease visit www.trinitybiotech.com.\n\n Contact:  Trinity Biotech plc  RedChip Companies Inc.       \n           Paul Murphy          Dave Gentry, CEO             \n           (353)-1-2769800      (1)-407-644-4256             \n                                (1)-800-RED-CHIP (733-2447)  \n                                TRIB@redchip.com             \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/23a9d0e4-6c22-4509-971e-0c09c45ec985)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX91PQ3L","title":"Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update","author":"Globe Newswire","ticker":"TRIB","created":"2026-08-28T21:15:00.108Z","tickers":["TRIB"],"exchange":"NASDAQ","article_body":"- Continued execution of transformation strategy drives commercial,\nmanufacturing and pipeline progress\n\n- PrePsia™ patent portfolio expands to nine granted U.S. and European\npatents\n\n- Company issues update on Nasdaq listing\n\nDUBLIN, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB),\na commercial-stage biotechnology company focused on human diagnostics and\ndiabetes management solutions, today provided an update on key developments\nacross its diagnostics business, highlighting continued commercial progress,\noperational transformation and diagnostic pipeline advancement.\n\nStrengthening Commercial Leadership in Europe\n\nTrinity Biotech is pleased to announce that Jordi Romero has joined the\nCompany as Head of Commercial Operations – Europe. Mr. Romero brings\nextensive experience in diagnostic sales, marketing and commercial leadership,\nincluding significant expertise within the haemoglobin diagnostics market. He\njoins Trinity at an important stage in the Company's transformation as it\nseeks to accelerate profitable growth across its diagnostics franchise in\nEurope and other international markets. \n\nMr. Romero's appointment forms part of Trinity's broader strategy to\nstrengthen its commercial organisation, deepen customer engagement and enhance\nexecution across key international markets.\n\nContinued Rollout of Upgraded HbA1c Column Technology\n\nThe Company also announced continued progress in the commercial rollout of its\nnext-generation high-capacity HbA1c column system for the FDA-cleared Premier\nHb9210™ analyser. Trinity has now successfully completed rollout of the\nupgraded column system in three of its largest international markets and is\nreceiving positive customer feedback regarding performance and overall user\nexperience.\n\nDesigned for Trinity Biotech’s Premier Hb9210™ analyser, the Company’s\ndedicated laboratory HbA1c solution, the upgraded column system delivers up to\nfour times the testing capacity compared to the existing column system and\nminimizes instrument downtime through improved stability and reduced\ncalibration requirements. These operational gains create a more efficient\nworkflow for clinical laboratories and support broader adoption of the\nplatform.\n\nThe Company expects continued deployment across additional markets over the\ncoming quarters.\n\nOperational Transformation Driving Margin and Working Capital Benefits\n\nTrinity continues to execute its comprehensive operational transformation\nprogramme, including the transition of significant portions of the\nmanufacturing process for its World Health Organization-approved rapid HIV\ntest portfolio to an outsourced manufacturing structure.\n\nThe Company has successfully completed manufacture of the previously announced\napproximately 9 million TrinScreen HIV tests under this new operating model\nand has now also commenced manufacture of Uni-Gold™ HIV utilising its\noutsourced manufacturing structure.\n\nThe Company remains focused on scaling Uni-Gold™ HIV production and has\ncurrently a strong order book for the product.\n\nOnce fully scaled, the Company expects the outsourced manufacturing model to\ndeliver meaningful improvements in gross margin performance, manufacturing\nefficiency and working capital utilisation.\n\nAs previously indicated, the transition and scale-up process may result in\nquarter-to-quarter variability in Uni-Gold™ HIV revenues during the ramp-up\nperiod as manufacturing output continues to increase and supply chain\ninventories are optimised.\n\nContinued Advancement of the Diagnostics Pipeline\n\nTrinity also continues to advance its pipeline of innovative diagnostic\nproducts.\n\nMost recently, the Company received a European patent covering the use of\nblood pressure-related metrics in its PrePsia™ early preeclampsia prediction\nplatform. This brings the total number of PrePsia™ related granted patents\nacross Europe and the United States to nine and further strengthens the\nintellectual property protection around the Company’s maternal health\nprogramme.\n\nPrePsia™ is being developed as an early screening test designed to identify\npregnancies at increased risk of preterm preeclampsia, one of the leading\ncauses of maternal and foetal morbidity worldwide. The Company believes the\ncontinued expansion of the intellectual property portfolio supporting\nPrePsia™, and its underpinning technologies, strengthens the foundation for\nfuture commercialisation opportunities in women's health diagnostics. \n\nThe Company intends to launch the PrePsia™ test through its existing New\nYork State Department of Health approved reference laboratory.\n\nTransformation Continues to Gain Momentum\n\nThe Company believes these achievements demonstrate continued execution\nagainst its strategy to transform Trinity Biotech into a more efficient,\ncommercially focused and innovation-driven diagnostics business.\n\nKey areas of progress include:\n* Strengthening commercial leadership and market execution.\n* Enhancing the competitiveness of the Premier Hb9210 platform.\n* Improving manufacturing efficiency through strategic outsourcing\ninitiatives.\n* Expanding intellectual property protection around high-value diagnostic\npipeline assets.\n* Positioning the business for sustainable margin expansion and profitable\ngrowth.\nNasdaq Notice \n\nAs previously reported in a Current Report on Form 6-K filed February  20,\n2026, on February  19, 2026, the Company received a deficiency letter from\nthe Listing Qualifications Department of The Nasdaq Stock Market LLC\n(“Nasdaq”) notifying the Company that, for the preceding 30 consecutive\nbusiness days, the market value of publicly held shares (\"MVPHS\") remained\nbelow the minimum $15 million for continued inclusion on The Nasdaq Global\nSelect Market pursuant to Nasdaq Listing Rule 5450(b)(3)(c) (the “MVPHS\nRequirement”). The Company was provided an extension of 180 calendar days,\nor until August 18, 2026, (the “Compliance Period”) to regain compliance\nwith the MVPHS Requirement. \n\nOn August 28, 2026, the Company received a staff determination letter (the\n“Determination Letter”) from the Staff notifying the Company that it had\nnot regained compliance with the MVPHS Requirement by August 18, 2026.\nAccordingly, and as described in the Determination Letter, unless the Company\ntimely requests a hearing before a Hearings Panel (the “Panel”), the\nCompany’s securities would be subject to suspension/delisting. Accordingly,\nthe Company intends to timely request a hearing before the Panel.\n\nThe Company has a number of initiatives and strategic transactions at advanced\nstages, which, if completed, would be expected to increase the Company’s\nMVPHS above the $15 million minimum. The Company intends to continue to\nprogress these transactions and as such management remains confident that the\nactions currently underway will enable the Company to reach a MVPHS of over\n$15 million.\n\nThe hearing request will automatically stay any suspension or delisting action\npending the hearing and the expiration of any additional extension period\ngranted by the Panel following the hearing. In that regard, pursuant to the\nNasdaq Listing Rules, the Panel has the authority to grant an extension not to\nexceed February 24, 2027.\n\nNotwithstanding the foregoing, there can be no assurance that the Panel will\ngrant the Company an additional extension period or that the Company will\nultimately regain compliance with all applicable requirements for continued\nlisting on The Nasdaq Global Select Market.  \n\nForward-Looking Statements\nThis release includes statements that constitute “forward-looking\nstatements” within the meaning of the Private Securities Litigation Reform\nAct of 1995 (the “Reform Act”), including but not limited to statements\nrelated to Trinity Biotech’s cash position, financial resources and\npotential for future growth, market acceptance and penetration of new or\nplanned product offerings, and future recurring revenues and results of\noperations. Trinity Biotech claims the protection of the safe harbor for\nforward-looking statements contained in the Reform Act. These forward-looking\nstatements are often characterized by the terms “may,” “believes,”\n“projects,” “expects,” “anticipates,” or words of similar import,\nand do not reflect historical facts. Specific forward-looking statements\ncontained in this release may be affected by risks and uncertainties,\nincluding, but not limited to, our ability to capitalize on the Waveform\ntransaction and our recent acquisitions, our continued listing on the Nasdaq\nStock Market, our ability to achieve profitable operations in the future, our\nability to successfully develop and commercialize data center cooling &\nthermal management solutions for AI and high-performance computing, the impact\nof the spread of COVID-19 and its variants, the possible pause and/or\ndisruption in U.S. Government funding for HIV tests produced by Trinity\nBiotech, potential excess inventory levels and inventory imbalances at the\nCompany’s distributors, losses or system failures with respect to Trinity\nBiotech’s facilities or manufacturing operations, the effect of exchange\nrate fluctuations on international operations, fluctuations in quarterly\noperating results, dependence on suppliers, the market acceptance of Trinity\nBiotech’s products and services, the continuing development of its products,\nrequired government approvals, risks associated with manufacturing and\ndistributing its products on a commercial scale free of defects, risks related\nto the introduction of new instruments manufactured by third parties, risks\nassociated with competing in the human diagnostic market, risks related to the\nprotection of Trinity Biotech’s intellectual property or claims of\ninfringement of intellectual property asserted by third parties, and risks\nrelated to the condition of the United States economy and other risks detailed\nunder “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for\nthe fiscal year ended December 31, 2025 and Trinity Biotech’s other periodic\nreports filed from time to time with the United States Securities and Exchange\nCommission. Forward-looking statements speak only as of the date the\nstatements were made. Trinity Biotech does not undertake and specifically\ndisclaims any obligation to update any forward-looking statements.\n\nAbout Trinity Biotech\nTrinity Biotech plc (NASDAQ: TRIB) is a commercial-stage biotechnology company\nfocused on human diagnostics and diabetes management solutions, including\nwearable biosensors. The Company develops, acquires, manufactures, and markets\ndiagnostic systems for the point-of-care and clinical laboratory segments of\nthe diagnostic market and has recently entered the wearable biosensor industry\nthrough the acquisition of biosensor assets from Waveform Technologies Inc.\nThrough its Trinovium subsidiary, Trinity Biotech is extending its fluid\nmanufacturing and analytical capabilities into advanced liquid cooling\nsolutions for AI data center infrastructure. Trinity Biotech sells directly in\nthe United States and through a network of international distributors and\nstrategic partners in over 75 countries worldwide. For further information,\nplease visit www.trinitybiotech.com.\n\n Contact:  Trinity Biotech plc  RedChip Companies Inc.       \n           Paul Murphy          Dave Gentry, CEO             \n           (353)-1-2769800      (1)-407-644-4256             \n                                (1)-800-RED-CHIP (733-2447)  \n                                TRIB@redchip.com             \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/23a9d0e4-6c22-4509-971e-0c09c45ec985)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-28T21:15:00.154701885Z","server_sent_at_ms":1787951700154},"received_at":"2026-08-28T21:15:00.219Z","source_url":null},"analysis":{"id":"119553","press_release_id":"130642","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Nasdaq delisting risk due to failure to maintain MVPHS compliance","Potential quarter-to-quarter revenue variability in Uni-Gold™ HIV during manufacturing ramp-up"],"eventType":"regulatory","narrative":"Trinity Biotech provided a business update highlighting operational improvements, including the appointment of Jordi Romero as Head of Commercial Operations for Europe and the expansion of its PrePsia patent portfolio to nine granted U.S. and European patents.\n\nThe company reported progress in its manufacturing transformation, having completed approximately 9 million TrinScreen HIV tests under an outsourced model and initiating production of Uni-Gold™ HIV tests.\n\nDespite commercial progress, the company received a staff determination letter from Nasdaq confirming it failed to regain compliance with the minimum $15 million market value of publicly held shares requirement by the August 18 deadline.\n\nManagement intends to request a hearing before a Nasdaq panel to automatically stay any suspension, expressing confidence that pending strategic transactions will restore compliance before the February 2027 extension deadline.","sentiment":"mixed","agentHooks":{"shouldPost":true,"suggestedAngle":"Operational momentum overshadowed by Nasdaq delisting notice; company seeks hearing to buy time for strategic transactions."},"keyFigures":{"customDimensions":{"patents_granted":9,"trinscreen_tests_manufactured":9000000}},"quotedText":"The Company has a number of initiatives and strategic transactions at advanced stages, which, if completed, would be expected to increase the Company’s MVPHS above the $15 million minimum.","namedEntities":{"people":[{"name":"Jordi Romero","role":"Head of Commercial Operations – Europe"}],"products":["PrePsia™","TrinScreen HIV","Uni-Gold™ HIV","Premier Hb9210™"],"companies":[{"name":"Trinity Biotech plc","ticker":"TRIB"},{"name":"The Nasdaq Stock Market LLC","relationship":"regulatory body"},{"name":"RedChip Companies Inc.","relationship":"investor relations"}],"dollarAmounts":[{"amount":"$15 million","context":"minimum market value of publicly held shares (MVPHS) required for Nasdaq listing"}]},"materialImpact":{"score":3,"reasoning":"Company received a Nasdaq determination letter for failing to meet MVPHS requirements, putting the listing at risk, though a hearing has been requested to stay suspension. Business fundamentals show progress with manufacturing scaling and patent expansion, offsetting some regulatory negativity."},"tickerRelevance":{"others":[],"primary":"TRIB"},"globalImportance":25,"audienceRelevance":15,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"delisting-risk","sectorWeight":"niche-diagnostics"}},"event_type":"regulatory","event_type_secondary":["operations_update"],"sentiment":"mixed","material_impact_score":3,"narrative":"Trinity Biotech provided a business update highlighting operational improvements, including the appointment of Jordi Romero as Head of Commercial Operations for Europe and the expansion of its PrePsia patent portfolio to nine granted U.S. and European patents.\n\nThe company reported progress in its manufacturing transformation, having completed approximately 9 million TrinScreen HIV tests under an outsourced model and initiating production of Uni-Gold™ HIV tests.\n\nDespite commercial progress, the company received a staff determination letter from Nasdaq confirming it failed to regain compliance with the minimum $15 million market value of publicly held shares requirement by the August 18 deadline.\n\nManagement intends to request a hearing before a Nasdaq panel to automatically stay any suspension, expressing confidence that pending strategic transactions will restore compliance before the February 2027 extension deadline.","key_figures":{"customDimensions":{"patents_granted":9,"trinscreen_tests_manufactured":9000000}},"named_entities":{"people":[{"name":"Jordi Romero","role":"Head of Commercial Operations – Europe"}],"products":["PrePsia™","TrinScreen HIV","Uni-Gold™ HIV","Premier Hb9210™"],"companies":[{"name":"Trinity Biotech plc","ticker":"TRIB"},{"name":"The Nasdaq Stock Market LLC","relationship":"regulatory body"},{"name":"RedChip Companies Inc.","relationship":"investor relations"}],"dollarAmounts":[{"amount":"$15 million","context":"minimum market value of publicly held shares (MVPHS) required for Nasdaq listing"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-28T21:17:37.549Z","global_importance":25,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"delisting-risk","sectorWeight":"niche-diagnostics"}},"durationMs":157317,"modelName":"glm-4.7"}}